Significant Publications on Infectious Diseases Pharmacotherapy in 2021

• Published in: Journal of Pharmacy Practice 2024-02, Vol.37 (1), p.198-211
• Main Authors: Nguyen, Nhi, Chua, Hubert C., Drake, Ty, Jo, Jinhee, Stramel, Stefanie Anne, Vuong, Nancy N., Gonzales-Luna, Anne J., Olson, Kelsey, on behalf of the Houston Infectious Diseases Network
• Format: Article
• Language: English
• ISSN: 0897-1900; 1531-1937
• DOI: 10.1177/08971900221128334

Purpose: To summarize the most noteworthy infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2021. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated articles that were deemed to have significant contributions to ID pharmacotherapy in 2021. These nominations included articles pertaining to both general ID, including coronavirus disease 2019 (COVID-19), and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. A total of 35 articles were nominated by HIDN: 30 articles pertaining to general ID pharmacotherapy and 5 articles with HIV/AIDS focus. To select the most influential articles of 2021, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Of the 239 SIDP members who responded to the survey, there were 192 recorded votes for the top 10 general ID pharmacotherapy articles and 47 recorded votes for the top HIV/AIDS article, respectively. The top publications are summarized. Conclusion: Antimicrobial stewardship and the optimal management of infectious disease states continues to be a priority in the midst of the ongoing coronavirus disease 2019 (COVID-19) global pandemic. In light of the sheer volume of ID-related articles published in the past year, this review aims to aid clinicians in remaining up-to-date on key practice-changing ID pharmacotherapy publications from 2021.